IN2014KN01037A - Methods and compositions for the treatment of diabetes and related symptoms - Google Patents

Methods and compositions for the treatment of diabetes and related symptoms

Info

Publication number
IN2014KN01037A
IN2014KN01037A IN1037/KOLNP/2014A IN1037KON2014A IN2014KN01037A IN 2014KN01037 A IN2014KN01037 A IN 2014KN01037A IN 1037KON2014 A IN1037KON2014 A IN 1037KON2014A IN 2014KN01037 A IN2014KN01037 A IN 2014KN01037A
Authority
IN
India
Prior art keywords
diabetes
compositions
treatment
related symptoms
glutamine
Prior art date
Application number
IN1037/KOLNP/2014A
Inventor
Yutaka Niihara
Original Assignee
Emmaus Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48470183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014KN01037(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emmaus Medical Inc filed Critical Emmaus Medical Inc
Publication of IN2014KN01037A publication Critical patent/IN2014KN01037A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention is directed to methods and compositions for the treatment of diabetes and related symptoms. It is more specifically directed to compositions including L glutamine its salts or its derivatives and uses of such compositions in the treatment of diabetes and related symptoms. In a method aspect the present invention provides a method of treating diabetes. The method involves ingesting 0.05 g/kg body weight to 10.0 g/kg body weight of L glutamine an L glutamine salt or an L glutamine derivative per day by a person who has diabetes.
IN1037/KOLNP/2014A 2011-11-21 2014-05-15 Methods and compositions for the treatment of diabetes and related symptoms IN2014KN01037A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161629633P 2011-11-21 2011-11-21
PCT/US2012/000557 WO2013077893A1 (en) 2011-11-21 2012-11-17 Methods and compositions for the treatment of diabetes and related symptoms

Publications (1)

Publication Number Publication Date
IN2014KN01037A true IN2014KN01037A (en) 2015-10-09

Family

ID=48470183

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1037/KOLNP/2014A IN2014KN01037A (en) 2011-11-21 2014-05-15 Methods and compositions for the treatment of diabetes and related symptoms

Country Status (10)

Country Link
US (2) US20130143968A1 (en)
EP (2) EP3437649A1 (en)
JP (4) JP6089042B2 (en)
CN (3) CN108478551A (en)
BR (1) BR112014011898A2 (en)
ES (1) ES2785094T3 (en)
HK (1) HK1257401A1 (en)
IN (1) IN2014KN01037A (en)
PH (1) PH12020550726A1 (en)
WO (1) WO2013077893A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (en) 2016-12-19 2019-06-18 Axcella Health Inc Amino acid compositions and methods for the treatment of liver diseases
JP7266581B2 (en) 2017-08-14 2023-04-28 アクセラ・ヘルス・インコーポレイテッド Amino acid composition for treatment of liver disease
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
WO2003002595A2 (en) * 2001-06-27 2003-01-09 Probiodrug Ag Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
SE0201713D0 (en) * 2001-11-23 2002-06-06 Gramineer Internat Ab New methods and use III
TWI351278B (en) * 2002-03-01 2011-11-01 Nisshin Pharma Inc Agent for preventing and treating of liver disease
US20070025953A1 (en) * 2005-07-27 2007-02-01 Jones Michael R Co-therapy for diabetic conditions
CA2774197A1 (en) * 2006-04-22 2008-04-03 Harbor Biosciences, Inc. Drugs and uses to modulate inflammation, metabolic disorders and other conditions
JP5294149B2 (en) * 2006-09-29 2013-09-18 味の素株式会社 Glutamine-containing composition for increasing blood flow
US20080221074A1 (en) * 2006-11-17 2008-09-11 Jaime Flores-Riveros Drug Screen and Treatment Method
EP2057905A1 (en) * 2007-11-12 2009-05-13 TIMA Foundation Composition for moderating Triglyceride and Cholesterol Levels
ES2628233T3 (en) * 2009-01-12 2017-08-02 Biokier Inc. Composition and method for the treatment of diabetes
NL1036746C2 (en) * 2009-03-20 2010-09-21 Glnp Holding B.V. KIT OF PARTS CONTAINING L-GLUTAMINE AND EGCG.
CA2774616A1 (en) * 2009-09-23 2011-03-31 Biokier, Inc. Composition and method for treatment of diabetes

Also Published As

Publication number Publication date
JP6089042B2 (en) 2017-03-01
EP2782588B1 (en) 2020-04-15
JP6550160B2 (en) 2019-07-24
JP2018115175A (en) 2018-07-26
PH12020550726A1 (en) 2021-06-14
JP2014533689A (en) 2014-12-15
WO2013077893A1 (en) 2013-05-30
CN103945858A (en) 2014-07-23
JP6389495B2 (en) 2018-09-12
EP2782588A1 (en) 2014-10-01
US20130143968A1 (en) 2013-06-06
JP2017052766A (en) 2017-03-16
CN108354916A (en) 2018-08-03
EP2782588A4 (en) 2015-05-20
HK1257401A1 (en) 2019-10-18
EP3437649A1 (en) 2019-02-06
JP2018199692A (en) 2018-12-20
ES2785094T3 (en) 2020-10-05
US20190192463A1 (en) 2019-06-27
BR112014011898A2 (en) 2017-05-16
CN108478551A (en) 2018-09-04

Similar Documents

Publication Publication Date Title
PH12020550726A1 (en) Method and compositions for the treatment of diabetes and related symptoms
JO3091B1 (en) Branched 3-phenylpropionic acid derivatives and their use
MX351464B (en) Methods for the treatment of allergic diseases.
MX349159B (en) Deuterated derivatives of ivacaftor.
EA201590371A1 (en) 1,4-DESIGNED PYRIDAZIN ANALOGUES AND METHODS OF TREATMENT RELATED TO SMN DEFICIENCY CONDITIONS
IN2014CN00562A (en)
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
MX360634B (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof.
MY170802A (en) Treatment of pulmonary disease
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
MX2013011691A (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses.
MX2015007916A (en) Peri-carbinols.
IN2015DN01151A (en)
MX2015009444A (en) Novel traps in the treatment of macular degeneration.
PH12015502302B1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
SG10201900541QA (en) Derivatives of xanthone compounds
MX2013002208A (en) Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes.
FI20115165A0 (en) Therapeutic and diagnostic methods
IN2014KN01255A (en) Methods and compositions for the treatment of diverticulosis
MX2016004909A (en) Composition containing eugenol as active ingredient for preventing or treating atopic dermatitis.
NZ707773A (en) Methods of treating liver diseases
IN2014DN00123A (en)
MX2021014120A (en) Treatment of androgen deprivation therapy associated symptoms.
MX2014003873A (en) Method of treating mucoepidermoid carcinoma.
IN2014DN08443A (en)